Skip to content

Clinical study of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19) based on CRISPR-cas protein

Development and application of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19) based on CRISPR-cas protein

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029810
Enrollment
Unknown
Registered
2020-02-14
Start date
2020-02-16
Completion date
Unknown
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 100 Years

Inclusion criteria

Inclusion criteria: Pneumonia cases with suspected SARS-CoV-2have either of the following epidemiological histories consistent with the following two clinical manifestations: A comprehensive analysis was conducted based on the following epidemiological history and clinical manifestations 1. Epidemiological history (1) Travel history or residence history of wuhan and surrounding areas or other communities shall provide case reports within 14 days before the onset of the disease; (2) Cases have been reported in the past 14 days in patients with fever or respiratory symptoms in community residents of wuhan and surrounding areas; (3) Aggressive attack; (4) History of exposure to new coronavirus infections people with new coronavirus infections are those who have tested positive for nucleic acid; 2. Clinical manifestations (1) Fever and/or respiratory symptoms; (2) Pneumonia with the above imaging features; (3) The total number of white blood cells was normal or decreased or the number of lymphocytes decreased at the initial stage of the disease.

Exclusion criteria

Exclusion criteria: Suspected patients with inability to collect deep sputum, throat swabs, or nose swabs from alveolar lavage.

Design outcomes

Primary

MeasureTime frame
SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactWeiren Huang

Shenzhen Second People's Hospital

pony8980@163.com+86 13923781386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026